Keywords: Novartis, Tianyuan, M&D, Vaccines, Research, China

Novartis makes another foray into China, buying Zheijian Tianyuan for $125 million

Article | 04 November 2009

Print This

Just a day after revealing a $1 billion-plus investment in China for R&D (The Pharma Letter November 3), Swiss drug ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in